Comments are off for this post

Cooley: #1 Firm for 2016 Life Sciences Deals

Palo Alto – January 19, 2017 – Singled out for M&A and IPO work, Cooley earned the top spot on Lake Whillans’ Life Sciences Law Firm Index. The index identifies the most active and relevant law firms for life sciences companies.

“Cooley is committed to providing the highest level of counsel to its life sciences clients,” said Barbara Kosacz, global chair of Cooley’s life sciences practice. “Our deep industry knowledge allows us to provide uniquely valuable insight to our clients as they continue to push boundaries.”

Cooley was recognized for advising Medivation on its $14 billion acquisition by Pfizer and Jazz Pharmaceuticals on its $1.5 billion acquisition of Celator. Lake Whillans also commended Cooley for its work advising Myovant Sciences on its $218 IPO, Protagonist Therapeutics on its $90 million IPO and the underwriters on NantHealth’s $97 million IPO.

Lake Whillans collects data in collaboration with its research partners Breaking Media, the publishers of MedCity News and Above the Law. The Top Deal Firms ranking considers all aspects of corporate and transactional practices, including mergers and acquisitions, IPOs, financing and private equity work.

Cooley counsels 1,200+ pharmaceutical, biotech and medtech companies around the world, including 50% of the NASDAQ Biotechnology Index.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Comments are closed.